AI scribes are now advertising like pharma. That tells you something

You know a medical technology has gone mainstream when it starts advertising like one. Heidi, the Australian clinical AI scribe company, has launched a global brand campaign that deliberately parodies pharmaceutical advertising: “Side effects may include relief, on repeat.” The campaign, made with agency Cocogun, runs across TV, YouTube, out-of-home and radio.

The medium is the message here. AI scribes spent two years selling to health systems through procurement decks. A brand campaign aimed at clinicians themselves, in pharma’s own visual language, signals a category that believes it has crossed from pilot tool to standard of care. The adoption data supports the confidence: as we covered in our read of Bessemer’s health AI report, 92 percent of US health systems were already deploying or piloting AI scribes, and two-thirds of clinicians use AI tools daily.

Heidi itself raised a $65 million Series B led by Point72 last October at a reported $465 million valuation, and says its platform processes millions of consultations weekly.

A physician’s caution about the pharma comparison

There is an irony in borrowing pharma’s aesthetic: drug ads carry that tone because the products behind them survived randomized trials and adverse-event reporting. Documentation AI is genuinely lower-risk, but the comparison invites a standard the category should be ready to meet, published accuracy rates, error taxonomies, and post-deployment monitoring. Marketing maturity should pull evidence maturity along with it, not substitute for it. The same gap shows up in new clinical tools: an NHS trust piloting an AI infection-risk score is being sold on a vendor claim that 85 percent of clinicians use it daily, a figure not yet independently audited.

What to watch

Watch whether rival scribes answer with consumer-style campaigns of their own, and whether clinician-directed marketing draws attention from health advertising regulators in the US and Australia, territory that pharma knows well and AI vendors are only beginning to map.